AMGN · Earnings call · 2026Q3T · Full report

Biosimilar Launch Competition

AMGEN INC · 2026-11-03 · Importance 26 · Surprise 24

Amgen described the OPDIVO and KEYTRUDA biosimilar market as competitive and declined to provide commercial launch timing. Management said it expects to launch these biosimilars first or in the first wave, which it views as important to establishing a competitive position. The company believes it is positioned to meet that timing based on its biosimilar track record.

Key facts

• Amgen expects to be first or in the first wave of biosimilar launches, which it considers important for establishing a competitive position.
• Amgen's biosimilar candidates for EYLEA HD, OPDIVO, KEYTRUDA, and OCREVUS were in late-stage clinical development.